A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate

Summary

A double blind randomized cross-over multi-center study has been conducted to compare the pharmacokinetic and coagulation activation markers of high-purity factor IX concentrate subjected to both solvent/ detergent (SD) treatment and 15 nm-filtration (FIX-SD-15) with the licensed product subjected only to solvent-detergent (FIX-SD). This filtration process allows the elimination of small particles, such as non-enveloped viruses (i.e., hepatitis A and parvovirus B19). Eleven severe hemophilia B patients (FIX coagulant activity <2 IU/dl) received one infusion of 60 IU/kg of FIX-SD and one infusion of 60 IU/kg of FIX-SD-15 at least at 10 days interval. Blood samples were obtained before and at various time up to 72 h after infusion. The decay curves of factor IX (FIX:C and FIX:Ag) were evaluated by a model independent method. Bioequivalence was found between the two concentrates using the Schuirmann test. The mean FIX:C and FIX:Ag recovery of FIX-SD-15 was 1.08 and 0.89 IU/dl/IU/kg respectively with a mean half-life of 33.3 h for FIX:C and 25.6 h for FIX:Ag. Six months after initial enrollment, pharmacokinetic parameters were similar in the 7 patients tested. There was no significant variation of prothrombin fragment 1+2 and thrombin-antithrombin complexes measured up to 6 h after infusion, indicating that there was no activation process after administration of FIX. In conclusion, these data demonstrate that the introduction of a 15 nm filtration does not alter the pharmacokinetic profile of a well characterized SD FIX concentrate while providing additional viral safety.

• References

• 1 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28 (Suppl. 06) 3-5.
• 2 Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of highly purified human plasma factor IX:C therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-32.
• 3 Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemi cal and in-vivo properties of high-purity factor IX concentrates. Thromb Haemost 1993; 70: 768-73.
• 4 Kim HC, McMillan CW, White II GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in haemophilia B patients and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-75.
• 5 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly-purified factor IX concentrate. Br J Haematol 1991; 79: 606-11.
• 6 Goudemand J, Marey A, Caron C, Wibaut B, Mizon P. Clinical efficacy of a highly-purified SD-treated factor IX concentrate prepared by conventional chromatography. Trans Med 1993; 3: 299-305.
• 7 Thomas DP, Hampton KK, Dasani H, Lee CA, Giangrande PLF, Harman C, Lee ML, Preston FE. A cross-over pharmacokinetic and thrombogeni-city study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haematol 1994; 87: 782-8.
• 8 Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EGD, Lowe GDO, Rumley A, Ludlam CA. High purity factor IX and prothrombin complex concentrate (PCC): Pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 1996; 76: 23-8.
• 9 Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvo-virus B19 in clotting concentrates : B19 DNA detection by the nested polymerase chain reaction. Br J Haematol 1992; 81: 407-12.
• 10 Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/ detergent-treated anti-haemophilia concentrates. Lancet 1994; 343: 211-2 (letter).
• 11 Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 1992; 339: 819 (letter).
• 12 Morfini M, Longo G, Ferrini PR, Azzi A, Zakrewska C, Ciappi S, Kolumban P. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus. Am J Hematol 1992; 39: 149 (letter).
• 13 Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994; 67: 132-8.
• 14 Chabbat J, Porte P, Tellier M, Boisgibault I, Marcilly H, Chtourou S. Validation of the nanofiltration of FIX-LFB : Biochemical and virological aspects. Thromb Haemost 1997; 77: 55 (abstract).
• 15 Gray E, Walker D, Heath A, Barrowcliffe TW. Collaborative study on assays of activated FIX (FIXa): On behalf of the factor VIII and factor IX subcommittee of the ISTH. Thromb Haemost 1996; 76: 1114-7.
• 16 Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-6.
• 17 Kasper CK, Aledort LM, Counts RB, Edson JR, Frantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levin PM, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J. A more uniform measurement of FVIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
• 18 Pearson TC, Guthie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults: Expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89: 748-56.
• 19 Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
• 20 Hafner G, Schinzel H, Ehenthal W, Wagner C, Konheiser U, Zotz R, Lotz J, Blank R, Weilemann LS, Prellwitz W. Influence of blood sampling from venipunctures and catheter systems on serial determination of prothrombin activation fragment 1+2 and thrombin-anti-thrombin complex. Ann Hematol 1993; 67: 121-5.
• 21 Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992; 81: 309-12.
• 22 Hampton KK, Preston FE, Lowe GDO, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993; 84: 279-84.
• 23 White GC II, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE. the Mononine study group. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with haemophilia B. Thromb Haemost 1995; 73: 779-84.
• 24 White GC II, Beebe A, Nielsen B. Recombinant Factor IX. Thromb Haemost 1997; 78: 261-5.
• 25 Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspect and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
• 26 Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: Methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
• 27 Mannucci PM, Tradati F. Preliminary in vivo evaluation of a nanofiltered factor IX concentrate. Thromb Haemost 1995; 73: 737-8.
• 28 Smith KJ, Thompson AR. Labeled factor IX kinetics in patients with haemophilia B. Blood 1981; 58: 625-9.
• 29 Amiral J. Personal communication.
• 30 Satoh S, Tateishi J, Sato T, Shepherd A, Macnaughton M. CHI’s Blood Safety Screening Conference. February 23-25 1998. McLean, VA; USA:
• 31 Goudemand J, Peynet J, Navarro R, Claeyssens S, Laurian Y, Gazengel C, Négrier C, Bertrand MA, Derlon A, Guérois C, Pautard B, Sultan Y, Parlier Y. Efficacy and safety of a high purity solvent-detergent and 15 nm filtered factor IX concentrate (FIXN). Interim analysis in 26 patients. Thromb Haemost 1997; 77: 53 (abstract).
• 32 Claeyssens S, Peynet J, Gazengel C, Alcalay M, Bertrnad MA, Briquel ME, Derlon A, Guérois C, d‘Oiron R, Pautard B, Sultan Y, Bridey F, Parlier Y, Goudemand J. Efficacy and safety of a solvent-detergent an 15 nm filtered factor IX concentrate in 16 elective surgical procedures in haemophilia B patients. Haemophilia 1998; 4: 191 (abstract).